| ¿µ¹® | platelet | ÇÑ±Û | Ç÷¼ÒÆÇ |
|---|---|---|---|
| ¼³¸í | °ñ¼öÀÇ °Å´ë ¼¼Æ÷ÀÎ °Å´ëÇÙ¼¼Æ÷ÀÇ ¼¼Æ÷Áú ÀϺΰ¡ ¶³¾îÁ®¼ ¼øÈ¯ Ç÷¾× Áß¿¡ ÃâÇöÇÑ °ÍÀ¸·Î Á÷°æÀÌ 2~4¥ìmÀÇ ÀÛÀº °ú¸³Ã¼ÀÌ´Ù. Ç÷¼ÒÆÇÀº ¼Õ»óÀ» ÀÔÀº Ç÷°üÀÇ ³ëÃâµÈ °áÇÕ Á¶Á÷¿¡ ºÙ¾î ¿©·¯ ¹°ÁúÀ» ºÐºñÇÏ¿© ÁöÇ÷ ¹× Ç÷¾× ÀÀ°í¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù. |
||
| ¿µ¹® | obsessive-compulsive disorder | ÇÑ±Û | °¹Ú¹ÝÀÀ¼º Àå¾Ö |
|---|---|---|---|
| ¼³¸í | °¹Ú»ç°í(obsession)Àº ¹Ýº¹µÇ´Â »ç°í¸¦ ¸»Çϸç, °¹ÚÇàÀ§(compulsion)´Â ¹Ýº¹µÇ´Â ÇൿÀ» ¸»ÇÑ´Ù. Áï ¹Ýº¹µÇ´Â »ç°í¿¡ µû¶ó ¹Ýº¹ÀûÀÎ ÇൿÀ» ¼öÇàÇÏ´Â Àå¾Ö¸¦ ¸»ÇÑ´Ù. À̶§ ¹Ýº¹ÀûÀÎ »ç°í´Â ÀÌ·ÐÀûÀ¸·Î ÀÌÇØµÇÁö ¾Ê´Â °æ¿ì°¡ ¸¹°í, º»Àεµ ÀÌ·± »ç°í°¡ ÀÌÇØµÇÁö ¾Ê´Â´Ù´Â »ç½ÇÀ» ¾Ë°í °íÄ¡·Á°í ÇÏÁö¸¸, Àß µÇÁö ¾Ê´Â´Ù. ¶ÇÇÑ °è¼ÓÀûÀ¸·Î ÀÌ·± »ç°í¿¡ µû¸¥ ¹Ýº¹ÀûÀÎ ÇൿÀ» Çϸç, ÀÌ·± ÇൿÀ» ¼öÇàÄ¡ ¾ÊÀ» ½Ã, º»ÀÎÀÇ ÀÇÁö¿Í ¹«°üÇÏ°Ô ¸÷½Ã ºÒ¾ÈÇØÇϰí, ÃÊÁ¶ÇØÇÑ´Ù. |
||
| ¿µ¹® | panic disorder | ÇÑ±Û | °øÈ²Àå¾Ö |
|---|---|---|---|
| ¼³¸í | ¹Ýº¹µÇ´Â °øÈ²¹ßÀÛ(panic attack: °©ÀÛ½º·± °øÆ÷»óÅÂÀÇ ¹ßº´)°ú ½Å°æ°ú¹ÎÀ» ³ªÅ¸³»´Â °æ¿ì¸¦ ¸»ÇÔ. °øÈ²¹ßÀÛÀº ´Üµ¶À¸·Î ÀϾ±âº¸´Ù´Â ¿À·£ ±äÀå»óÅ¿¡¼ ÁÖ±âÀûÀ¸·Î ÀϾ´Â Çö»óÀ¸·Î º¸ÀδÙ. °øÈ²¹ßÀÛÀÇ Áõ»óÀº ±Þ°ÝÇÑ ÀÚÀ²½Å°æÀÚ±ØÁõ»óÀ¸·Î È£Èí°ï¶õ, ½ÉÀå¹Úµ¿Ç×Áø, ÈäºÎÅëÁõ, ÈäºÎ¾Ð¹Ú°¨, Áú½Ä°¨, Çö±âÁõ, ºÒ¾ÈÁ¤ÇÑ ´À³¦ µîÀÌ´Ù. ´ë°³ °©ÀÚ±â ÀϾ ¼öºÐµ¿¾È Áö¼ÓÇß´Ù°¡ ¼Ò½ÇµÇ´Â °ÍÀÌ º¸ÅëÀÌ´Ù. µå¹°°Ô´Â ¼ö½Ã°£ Áö¼ÓµÇ±âµµ ÇÑ´Ù. °øÈ²¹ßÀÛÀº ÁÖ±âÀûÀ¸·Î ¹Ýº¹µÇ¸é¼ ¸¸¼ºÈÇÏ´Â °æÇâÀÌ ¸¹´Ù. ½Å°æ°ú¹ÎÀº °øÈ²¹ßÀÛÀÌ ¾ø´Â ½Ã±âÀÇ Áõ»óÀÌ´Ù. °¨´çŰ ¾î·Á¿î °øÈ²¹ßÀÛ¿¡ ´ëÇÑ ¿¹±âºÒ¾È(±× ÀÏÀÌ ÀϾÁö ¾ÊÀ»±î ÇÏ´Â ´À³¦ ¶§¹®¿¡ ¿À´Â ºÒ¾È)ÀÌ ÀÖ°í ±× ¶§¹®¿¡ Á¶½É½º·¯¿öÁö°í ÁÖÀ§¸¦ »ìÇǴ ŵµµµ ³ªÅ¸³ª¼ ½Å°æÀº ±Øµµ·Î ³¯Ä«·Î¿öÁø´Ù. °øÆ÷Àå¾Ö¿¡¼µµ ÀÌ·± °øÈ²¹ßÀÛÀÌ ¿Ã ¼ö ÀÖÀ¸³ª, ÀÌ °æ¿ì´Â Ưº°ÇÑ ´ë»óÀ̳ª »óȲÀÌ ÀÖ´Â °Í¿¡ ¹ÝÇØ °øÈ²Àå¾Ö´Â ÀÌ·± Ưº°ÇÑ »ç°Ç¾øÀÌ ÁÖ±âÀûÀ¸·Î ¹ß»ýÇÑ´Ù. Ä¡·á´Â Ç׺ҾÈÁ¦¿Í ¶§·Î´Â Ç׿ì¿ïÁ¦¸¦ »ç¿ëÇÑ´Ù. |
||
| ¿µ¹® | antisocial personality disorder | ÇÑ±Û | ¹Ý»çȸÀûÀΰÝÀå¾Ö |
|---|---|---|---|
| ¼³¸í | Áö¼ÓÀûÀ¸·Î ±×¸®°í ¸¸¼ºÀûÀ¸·Î ¹Ý»çȸÀûÀÎ ÇൿÀ» ÇÏ´Â Á¤½Å°úÀû º´. ´Ù¸¥ »ç¶÷¿¡°Ô Áø½Ç¼ºÀÌ ¾ø°í ´Ù¸¥ »ç¶÷ÀÇ ±Ç¸®³ª ÇÇÇØ¿¡´Â ÀüÇô ¹«°¨°¢ÇÏ°í ´ÜÁö ÀÚ½ÅÀÇ Ãæµ¿°ú ¿å±¸¿¡ ÀÇÇØ¼ ÇൿÀ» ÇÑ´Ù. ÀÚ½ÅÀÇ ½Ç¼ö¿¡ ´ëÇØ¼ ´Ù¸¥ »ç¶÷ÀÌ Ãæ°íÇÏ´Â °ÍÀ» ÂüÁö¸øÇϰí Ç×»ó ÀÚ½ÅÀÇ ¸¶À½´ë·Î¸¸ ÇÑ´Ù. |
||
| ¿µ¹® | anxiety disorder | ÇÑ±Û | ºÒ¾ÈÀå¾Ö |
|---|---|---|---|
| ¼³¸í | ½É¸®Àû ºÒ¾ÈÁ¤À̳ª ºÒ¾È µîÀ» ÁÖ Æ¯Â¡À¸·Î ÇÏ´Â Á¤½Å°úÀû º´ÅÂ. ´ëÇ¥ÀûÀÎ ¿¹·Î´Â °øÆ÷Áõ(phobia)¿Í °øÈ²Àå¾Ö(panic disorder), Àü¹ÝÀû ºÒ¾ÈÀå¾Ö(generalized anxiety disorder) µîÀÌ ÀÖ´Ù. °øÆ÷ÁõÀ̶õ ƯÁ¤ÇÑ Àå¼Ò³ª »óȲ¿¡ ´ëÇØ¼ º´ÀûÀÎ ºÒ¾ÈÀ» ´À³¢´Â °ÍÀ¸·Î ±¤Àå°øÆ÷Áõ(agoraphobia): Ź Æ®ÀÎ °ø°£À» ¹«¼¿öÇÔ. »çȸ°øÆ÷Ãþ(social phobia): ´Ù¸¥ »ç¶÷¾Õ¿¡ ¼´Â °ÍÀ» ¹«¼¿ö ÇÔ. °í¼Ò°øÆ÷Ãþ(acrophobia): ³ôÀº °÷¿¡ °¡´Â °ÍÀ» ¹«¼¿öÇÔ. ÁøÆó°øÆ÷Áõ(claustrophobia): ¹ÐÆóµÈ °ø°£À» ¹«¼¿öÇÔ. µ¿¹°°øÆ÷Áõ(zoophobia): µ¿¹°À» º´ÀûÀ¸·Î ¹«¼¿öÇÔ µîÀ» Æ÷ÇÔÇÑ´Ù. °øÈ²Àå¾Ö(panic disorde)¶õ ¿ÜºÎÀÇ À§ÇèÇÑ ÀÚ±ØÀÌ ¾ø´Âµ¥µµ ºÒ±¸ÇÏ°í °©Àڱ⠱ؽÉÇÑ °øÆ÷¸¦ ´À³¢´Â °ÍÀ» ¸»ÇÑ´Ù. ´ë°³ ½ÉÀåÀÌ ½ÉÇÏ°Ô ¶Ù°Å³ª ½ÄÀº ¶¡À» È긮°í, ½Ç½Å, È£Èí°ï¶õ µîÀÇ Áõ»óÀ» µ¿¹ÝÇÑ´Ù. Àü¹ÝÀû ºÒ¾ÈÀå¾Ö(generalized anxiety disorder)¶õ 1°³¿ùÀÌ»ó Áö¼ÓÀûÀÎ ºÒ¾ÈÀ» ´À³¢´Â °ÍÀ» ¸»ÇÑ´Ù. ´ë°³ »ç¼ÒÇÑ ÀÏ»óÀÇ ÀÏ¿¡ ´ëÇÑ ºÒ¾ÈÀ» ´À³¢¸ç, ºÒ¾ÈÀÇ ´ë»óÀÌ ¾ø´Â °æ¿ì¿¡´Â ¾ðÁ¦ ºÒ¾ÈÀ» ´À³¥Áö ¸ð¸¥´Ù´Â ºÒ¾È°¨(¿¹±âºÒ¾È)À» È£¼ÒÇÑ´Ù. ´ë°³ ¼è¾à, ¾îÁö·¯¿ò, ¼Õ¶³¸², ¶¡À» È긮´Â µîÀÇ ½ÅüÀû Áõ»óÀ» µ¿¹ÝÇÑ´Ù. |
||
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
|---|---|
| PA | panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'... |
| BD | barbital-dependent; barbiturate dependence; base deficit; base of prism down; basophilic degeneratio... |
| DD | dangerous drug; data definition; day of delivery; degenerated disc; degenerative disease; delusional... |
| PAD | pain and distress; patient surface axis depth; percutaneous abscess drainage; percutaneous automated... |
| ASD | Acute Stress Disorder |
|---|---|
| AD | Affective disorder |
| AUD | Alcohol Use Disorder |
| AUDIT | Alcohol Use Disorder Identification Test |
| APD | Antisocial Personality Disorder |
| acquired platelet function defect | <haematology> Platelet function can be affected by a number of different disease processes including polycythaemia vera, leukaemia, myelofibrosis, renal failure, multiple myeloma and some medications (for example penicillins, salicylates, phenothiazines). Disturbed blood clotting can be manifested by: easy bruising, bleeding gums, nosebleeds, abnormal vaginal bleeding, rectal bleeding, skin rash, vomiting blood, coughing up blood or blood in the urine. A measure of bleeding time and coagulation profile will be part of the evaluation. (29 Dec 1997) |
|---|---|
| antigens, human platelet | Human alloantigens expressed only on platelets, specifically on platelet membrane glycoproteins. These platelet-specific antigens are immunogenic and can result in pathological reactions to transfusion therapy. (12 Dec 1998) |
| anti-platelet agents | Medications that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| receptors, platelet-derived growth factor | Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain. (12 Dec 1998) |
| medication, anti-platelet | Platelet-blocking drugs. Drugs that, like aspirin, reduce the tendency of platelets in the blood to clump and clot. (12 Dec 1998) |
| platelet | <haematology> A discoid cell (3m diameter) found in large numbers in blood, important for blood coagulation and for haemostasis by repairing breaches (small breaks) in the walls of blood vessels. Platelet _ granules contain lysosomal enzymes, dense granules contain ADP (a potent platelet aggregating factor) and serotonin (a vasoactive amine). They also release platelet-derived growth factor which presumably contributes to later repair processes by stimulating fibroblast proliferation. Synonym: thrombocytes. (09 Oct 1997) |
| platelet-activating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet activation | A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug. (12 Dec 1998) |
| platelet actomyosin | The contractile protein of platelets, responsible for clot retraction, platelet aggregation, and release of ADP and other biologic amines essential to platelet function. Synonym: thrombosthenin. (05 Mar 2000) |
| platelet adhesiveness | The process whereby platelets adhere to something other than platelets, e.g., collagen, basement membranes, microfibrils, or other "foreign" surfaces. (12 Dec 1998) |
| platelet-aggregating factor | <cytokine> Potent phospholipid activator and mediator of many leucocyte functions, including platelet aggregation, inflammation, and anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, including neutrophils, basophils, platelets, and endothelial cells. Several molecular species of platelet-activating factor have been identified which vary in the length of the O-alkyl side chain. It is an important mediator of bronchoconstriction. Synonym: platelet-aggregating factor. Acronym: PAF (20 Sep 2002) |
| platelet aggregation | The attachment of platelets to one another. This clumping together can be induced by a number of agents (e.g., thrombin, collagen) and is part of the mechanism leading to the formation of a thrombus. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |
| platelet aggregation test | A test of the ability of platelets to adhere to each other and hence form a haemostatic plug to prevent bleeding; failure to aggregate occurs in several conditions, e.g., thrombasthenia, Von Willebrand's disease, and following administration of aspirin, phenylbutazone, and indomethacin; the test is conducted by quantitating the decrease in turbidity that occurs in platelet-rich plasma following the in vitro addition of one or several platelet-aggregating agents (e.g., ADP, epinephrine, or serotonin). (05 Mar 2000) |
| platelet basic protein | <protein> Protein that is the precursor of connective tissue activating peptide III and _ thromboglobulin. (18 Nov 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|